CYAD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 geg. 2023 @ 23:00):

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer...

Stats
Dzisiejszy wolumen	48 998.00
Średni wolumen	18 057.00
Kapitalizacja rynkowa	14.24M
EPS	$0 ( 2023-03-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.320
ATR14	$0.103 (21.91%)

Wolumen Korelacja

Długi: 0.39 (neutral)

Krótki: -0.71 (moderate negative)

Signal:(32.982) Neutral

Celyad SA Korelacja

10 Najbardziej pozytywne korelacje
GAINL	0.944
BTBD	0.867
OXBR	0.856
NXTP	0.853
CLLS	0.85
BLI	0.84
DZSI	0.84
CALT	0.836
CVAC	0.827
SIFY	0.824

10 Najbardziej negatywne korelacje
RMRM	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celyad SA Korelacja - Waluta/Towar

-0.60
( weak negative )

-0.55
( weak negative )

0.00
( neutral )

-0.45
( neutral )

-0.02
( neutral )

0.56
( weak )

Celyad SA Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-1.810

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-1.810

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.844

FY	2020
Przychody:	$5 000.00
Zysk brutto:	$5 000.00 (100.00 %)
EPS:	$-1.230

Financial Reports:

No articles found.

Celyad SA

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.